Getting FDA approval, a base hit.
Getting reimbursement, that’s the ball game.

Introduction Bringing any new medical product or service to market is quite difficult. Bringing a new or emerging healthcare technology to market is that much more complicated, with an end-to-end commercialization process that includes robust research and development, clinical trials, data collection and analysis, the regulatory pathway and reimbursement. It is predominantly believed that navigating… Continue reading Getting FDA approval, a base hit.
Getting reimbursement, that’s the ball game.

Published
Categorized as Blog

1,112 Patient Study Demonstrates Clinical Utility and Care Benefits of KidneyIntelX™ Risk Stratification in Stage 1 to 3 Diabetic Kidney Disease Patients

Late-breaking data presented at American Diabetes Association Scientific Sessions® demonstrates increased adherence to care guidelines for physicians using KidneyIntelX risk assessment to improve outcomes, alleviate patient suffering, and reduce significant financial burden associated with rapidly

Read More

Published
Categorized as News

KidneyIntelX™ Demonstrates Ability to Assess Risk of Heart Failure Hospitalization and Death in Large International Diabetic Kidney Disease Patient Cohort

Data shared in oral presentation at American Diabetes Association 82 nd Scientific Sessions® and published in Kidney360 highlights importance in early understanding of cardiovascular risk, a leading cause of death in patients with diabetes and chronic kidney disease NEW YORK and SALT LAKE CITY,

Read More

Published
Categorized as News

Renalytix plc Issue of shares

NEW YORK and SALT LAKE CITY, April 08, 2022 (GLOBE NEWSWIRE) — Renalytix Plc (NASDAQ: RNLX) (LSE: RENX) announces that under the Company’s Employee Share Purchase Plan (the “ESPP”), 22,814 new ordinary shares of £0.0025 each in the capital of the Company (the “Ordinary Shares”) have been issued to

Read More

Published
Categorized as News